ADMINISTERING_IC: AG

IC_NAME: NATIONAL INSTITUTE ON AGING

NIH_SPENDING_CATS: Aging;Autoimmune Disease;Behavioral and Social Science;Cardiovascular;Clinical Research;Lupus;Physical Activity;Prevention;Telehealth

ORG_CITY: New York

ORG_NAME: HOSPITAL FOR SPECIAL SURGERY

PHR: PROJECT NARRATIVE Physical activity (PA) is especially important in aging adults with systemic lupus erythematosus, who have significantly higher rates of cardiovascular disease and multiple chronic conditions than their peers without lupus. PA programming tailored to older adults with lupus is essential to meet their unique needs. The objective of this proposal is to determine overall PA levels, perceived impediments to and facilitators of PA, and readiness to participate in a digital PA program in a sample of older (50 years of age and above) adults with lupus, with the ultimate goal of improving their overall health and wellbeing.

PI_NAMEs: LIEBER, SARAH BETH (contact)

PROGRAM_OFFICER_NAME: JOSEPH, LYNDON

PROJECT_TERMS: 18 year old;acceptability and feasibility;Address;Adult;age related decline;Age Years;Aging;Behavior;Behavior Therapy;bone quality;Cardiovascular Diseases;Characteristics;chronic pain;Collection;common symptom;community-level factor;Data;design;digital;digital delivery;digital health;digital tool;Dimensions;Dissemination and Implementation;Education;empowerment;evidence base;Exclusion;Exercise;exercise intervention;Exercise Therapy;experience;Fatigue;Foundations;frailty;Future;General Population;Goals;Guidelines;Health;Health Technology;improved;indexing;Individual;interest;International;Intervention;Interview;life span;Lupus;meetings;Mentors;middle age;Modeling;modifiable risk;mortality;Motivation;multidisciplinary;multiple chronic conditions;Muscle;Musculoskeletal;older adult;Outcome;peer;peer support;Personal Satisfaction;Physical activity;pilot test;Population;preference;Prevalence;programs;Questionnaires;Readiness;Recommendation;remote delivery;Reporting;Research;Resources;rheumatologist;Risk Factors;Sampling;sedentary lifestyle;Social support;Structure;Surveys;System;Systemic Lupus Erythematosus;Tablets;Target Populations;Technology;Therapeutic;tool;Vulnerable Populations;Work

PROJECT_TITLE: Physical Activity Behaviors and Readiness for a Digital Health Physical Activity Intervention inOlder Adults with Systemic Lupus Erythematosus


ADMINISTERING_IC: CA

ARRA_FUNDED: N

FUNDING_MECHANISM: RESEARCH CENTERS

IC_NAME: NATIONAL CANCER INSTITUTE

NIH_SPENDING_CATS: Cancer;Cancer Genomics;Clinical Research;Clinical Trials and Supportive Activities;Genetics;Hematology;Human Genome;Rare Diseases

ORG_CITY: SCOTTSDALE

ORG_COUNTRY: UNITED STATES

ORG_FIPS: US

ORG_NAME: MAYO CLINIC ARIZONA

ORG_STATE: AZ

PHR: PROJECT NARRATIVE While our studies have confirmed the significant role of the disrupted genome in Multiple Myeloma (MM), they have also re-emphasized the gaps in understanding, and the importance of immune regulation and gene- environment interaction. To address this, we will leverage a carefully studied and homogeneously treated high- risk group of “double hit” patients to create the first unbiased multi-omics atlas of MM. We will perform a series of complex analyses to identify MM-associated changes in and across the genome, transcriptome, epigenome, immune environment, proteome, lipidome and metabolome. This will reveal insights into biological pathways influencing MM responsiveness to therapy and subsequent outcomes, and create the High Definition MM Scientific resource, a unique data compendium derived from blood and marrow samples linked to a detailed clinical trial data set.

PI_NAMEs: BRAGGIO, ESTEBAN  (contact)

PROJECT_TERMS: Accounting;Address;Atlases;Automobile Driving;biobank;bioinformatics tool;Biological;Blood;Bone Marrow;Caring;Cells;Clinic;Clinical;Clinical Data;clinical database;clinical phenotype;clinical risk;Clinical Trials;Collaborations;Complex;Complex Analysis;Core Facility;Data;Data Analyses;Data Analytics;data integration;data resource;Data Set;deep learning;design;Disease;Disease Outcome;DNA;DNA sequencing;drug sensitivity;Environment;Epigenetic Process;epigenome;Event;Evolution;experience;gene environment interaction;gene interaction;Generations;Genes;Genetic;Genome;Genomics;Goals;high risk;high risk population;Immune;Immuno-Chemotherapy;Immunophenotyping;immunoregulation;improved;Individual;insight;Link;lipidome;Maps;Marrow;Mass Spectrum Analysis;metabolome;Mononuclear;mRNA sequencing;multidisciplinary;Multiomic Data;Multiple Myeloma;multiple omics;Mutation;neoplastic cell;Network-based;Outcome;Pathogenesis;Pathway interactions;patient population;Patients;Pattern;personalized approach;Phase II Clinical Trials;Phenotype;Pilot Projects;Population;Positioning Attribute;Process;Proteome;Relapse;Resistance;Resolution;Resources;response;Rewards;RNA;Role;Sampling;Sampling Studies;Series;single cell analysis;Specimen;Technology;therapeutically effective;Time;transcriptome;transcriptomics;translational clinical trial;treatment response;tumor;tumor-immune system interactions;ultra high resolution;Variant;whole genome;Work

PROJECT_TITLE: Project 2: Multi-Omics of high-risk MM


ADMINISTERING_IC: DK

IC_NAME: NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES

NIH_SPENDING_CATS: Behavioral and Social Science;Diabetes;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Nutrition;Prevention;Social Determinants of Health

ORG_CITY: ANN ARBOR

ORG_NAME: UNIVERSITY OF MICHIGAN AT ANN ARBOR

ORG_STATE: MI

PI_NAMEs: KULLGREN, JEFFREY  (contact)

PROJECT_TERMS: Address;Age;behavior change;behavior influence;Behavioral;behavioral economics;Behavioral Sciences;care seeking;career;Collaborations;Community Healthcare;cultural competence;Diabetes Mellitus;Diabetes prevention;Diet;Disparity;disparity elimination;disparity reduction;Economics;Environment;Evaluation;experience;Faculty;Health;Health behavior;Health behavior and outcomes;health care settings;health determinants;health disparity populations;health equity promotion;improved;improved outcome;Individual;Inequity;innovation;insight;Intervention;Intervention Studies;Knowledge;Learning;Measurement;Measures;Mediator;Medical;medication compliance;Michigan;Morbidity - disease rate;mortality;multidisciplinary;next generation;novel;Outcome;outcome disparities;patient population;perceived discrimination;Persons;Physical activity;Play;poor health outcome;Positioning Attribute;Prevention;psychosocial;Public Health;Research;Research Personnel;Self Management;social;social health determinants;social influence;Structural Racism;System;Translational Research;treatment disparity;Work

PROJECT_TITLE: Addressing Social and Behavioral Determinants of Health


NIH_SPENDING_CATS: Cancer;Clinical Research;Genetics;Hematology;Orphan Drug;Prevention;Rare Diseases

PHR: PROJECT NARRATIVE Recent data suggests that the early detection and treatment of multiple myeloma results in improved clinical outcomes. The proposed research will develop a genetic definition of multiple myeloma that will improve early detection. This will lead to early treatment aimed at reducing illness, preventing disability and prolonging life.

PI_NAMEs: CHESI, MARTA  (contact)

PROJECT_TERMS: Affect;Anemia;Anti-Inflammatory Agents;Automobile Driving;Benign;biobank;BIRC2 gene;Blood;bone;Bone Marrow;BRAF gene;CDKN2C gene;Cells;Chromosome abnormality;Chronic;Clinic;Clinical;clinical biomarkers;Clinical Trials;cohort;Collection;Combined Modality Therapy;Cytogenetics;Data;Diagnosis;Disability prevention;Disease;DNMT3a;Early Diagnosis;Early intervention trials;Early treatment;Enhancers;Enrollment;Event;FGFR3 gene;gene translocation;Genetic;Growth;Heart Diseases;Hematopoiesis;high risk;Hypercalcemia;IL6 gene;immune modulating agents;Immunoglobulin Genes;improved;Individual;Inflammation;inflammatory marker;Intervention;Intervention Trial;Kidney Failure;KRAS2 gene;Lesion;Life;Lymphoma;Malignant - descriptor;Malignant Neoplasms;malignant state;MAP Kinase Gene;MDM2 gene;Molecular Abnormality;Monoclonal gammopathy of uncertain significance;mouse model;Multiple Myeloma;Mus;mutant;Mutation;Myeloid Cells;Nature;next generation sequencing;NF-kappa B;NF1 gene;novel therapeutics;Organ;Outcome;Pathway interactions;Patients;Persons;Pharmaceutical Preparations;Plasma Cell Neoplasm;Plasma Cells;Population;pre-clinical;Prevention;Prognosis;progression risk;prospective;Proteins;PTPN11 gene;randomized, clinical trials;RB1 gene;Recurrence;Reporting;Research;Risk;Role;Sampling;Subgroup;therapeutic target;Time;TNF receptor-associated factor 3;TP53 gene;TRAF2 gene;treatment response;Tumor Burden;tumor microenvironment

PROJECT_TITLE: Project 3: Early detection and prevention of MM progression


NIH_SPENDING_CATS: Behavioral and Social Science;Diabetes;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Prevention;Social Determinants of Health

PI_NAMEs: WATKINS, DAPHNE  (contact)

PROJECT_TERMS: Address;Affect;anti-racism;Biological;career;Characteristics;Communication;Communities;Community Health Aides;Community Healthcare;Consultations;design;Development;diabetes management;Diabetes Mellitus;Diabetes prevention;Disease;Economics;Ecosystem;Educational workshop;Electronic Mail;Evaluation;Family;family influence;family support;Funding;Health;health equity;Healthcare Systems;improved;Individual;Inequity;instrument;interest;Intervention;Life;Link;Medical;member;Mental Health;Michigan;Modeling;North Carolina;online community;outreach;Participant;Patients;peer;peer influence;peer support;Prevention;Process;programs;racism;Research;Research Personnel;Research Project Grants;Research Proposals;Resources;Role;Shapes;social;Social Network;special interest group;symposium;Time;Training;translational applications;Translational Research;United States;Universities;Visit;webinar;Work

PROJECT_TITLE: National Community, Family, and Peer Support Core


NIH_SPENDING_CATS: Cancer;Hematology;Rare Diseases

PHR: PROJECT NARRATIVE: Developmental Research Program The Developmental Research Program will support new and highly innovative approaches to better characterize and treat multiple myeloma with the aim of improving overall survival and quality of life of myeloma patients. It is envisioned that these novel translational pilot projects in myeloma research would mature into full projects or other independent NIH grants as a result of seed-funding from the Developmental Research Program.

PI_NAMEs: VACHON, CELINE M (contact)

PROJECT_TERMS: Area;Basic Science;Clinic;Clinical;Clinical Investigator;Clinical Research;clinical translation;Clinical Trials;Collaborations;Death Rate;Development;Discipline;Fostering;Foundations;Funding;Future;Goals;Grant;improved;improved outcome;Incidence;Infrastructure;innovation;Laboratory Study;Mayo Clinic Cancer Center;Monitor;Multiple Myeloma;novel;Patients;Pilot Projects;programs;Quality of life;Recommendation;Research;Research Personnel;Research Project Grants;Research Support;Scientist;sound;Techniques;Testing;Translating;Translational Research;translational study;tumor;United States National Institutes of Health

PROJECT_TITLE: Developmental Research Program


NIH_SPENDING_CATS: Clinical Research;Diabetes;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Nutrition;Social Determinants of Health

PI_NAMEs: HERMAN, WILLIAM H (contact)

PROJECT_TERMS: Acceleration;Applications Grants;Award;Behavioral;career;Career Mobility;Clinical;Collaborations;Data;Development;Diabetes Mellitus;Diabetes prevention;Expenditure;Extramural Activities;Faculty;Fostering;Funding;Funding Agency;Goals;Grant;Health;health equity;Health equity research;Healthcare;improved;innovation;Institution;Interdisciplinary Study;interest;Intervention;Investments;medical schools;member;Mentorship;Michigan;Modeling;Monitor;National Institute of Diabetes and Digestive and Kidney Diseases;nutrition;Obesity;outreach;Paper;Pathway interactions;Peer Review;population health;Productivity;programs;Public Health Schools;Publications;Publishing;Research;Research Personnel;Research Project Grants;Research Proposals;Research Support;Resources;School Nursing;Schools;social;social health determinants;Social Work;Translational Research;Translations;United States National Institutes of Health;Universities

PROJECT_TITLE: Pilot and Feasibility Program


PHR: PROJECT NARRATIVE The purpose of this program is to support and mentor young investigators at the junior faculty level so that they can become outstanding translational investigators with a primary focus on multiple myeloma. Each individual selected for the project is provided 2 years of salary support ($50,000 per year). Each awardee is expected to spend the 2 years engaged in multiple myeloma translational research under the aegis of a suitable mentor. Again, support for only one of these individuals is being requested by the grant. Developmental funds from the Mayo Comprehensive Cancer Center will.

PI_NAMEs: FONSECA, RAFAEL  (contact)

PROJECT_TERMS: Advocate;Agreement;Area;Award;base;Benign;Bioinformatics;Biological Specimen database;Biometry;Bispecific Antibodies;Cancer Research Project;candidate selection;career;Clinic;Clinical;clinical database;Clinical Investigator;Clinical Trials;Collaborations;Communities;Comprehensive Cancer Center;design;Development;Early Diagnosis;Faculty;Fostering;Foundations;Functional disorder;Funding;Genetic;Goals;Grant;Group Meetings;Hematologic Neoplasms;high risk;Immune response;improved;Individual;Infrastructure;innovation;Institution;Integration Host Factors;Interdisciplinary Study;interest;Joints;Laboratories;Malignant - descriptor;Malignant Neoplasms;Mayo Clinic Cancer Center;Mentors;Mentorship;Minority;multidisciplinary;Multiple Myeloma;multiple omics;NCI-Designated Cancer Center;novel;Patients;Peer Review;Peer Review Grants;Prevention;Productivity;Prognosis;programs;Publications;Regimen;Research;Research Personnel;Research Project Grants;Research Proposals;Research Support;Resources;Risk;Series;Site;sound;success;survivorship;System;Training Activity;Translating;translational cancer research;Translational Research;translational scientist;Tumor Biology;tumor microenvironment;Vesicular stomatitis Indiana virus;Virotherapy;Wages;Woman

PROJECT_TITLE: Career Enhancement Program


NIH_SPENDING_CATS: Diabetes;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Prevention

PI_NAMEs: HEISLER, MARY ELLEN MICHELE (contact)

PROJECT_TERMS: Behavioral;Clinical;Collaborations;community building;Community Health Services;Community Medicine;community setting;Complex;Dedications;Diabetes Mellitus;Diabetes prevention;dissemination science;Educational workshop;Ethnic Origin;Feedback;Goals;Health;health determinants;health equity;Health Policy;Health system;implementation science;improved;Individual;innovation;International;Intervention;Michigan;multimodality;novel;novel strategies;Participant;Personal Satisfaction;Persons;Poverty;prevent;Prevention approach;programs;Research;Research Methodology;Research Personnel;Series;social;symposium;Training and Education;Training Programs;Translational Research;translational scientist

PROJECT_TITLE: Enrichment Program


ADMINISTERING_IC: AR

FUNDING_MECHANISM: SBIR-STTR RPGS

IC_NAME: NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES

NIH_SPENDING_CATS: Bioengineering;Biotechnology;Congenital Structural Anomalies;Genetics;Orphan Drug;Pediatric;Rare Diseases;Stem Cell Research;Stem Cell Research - Induced Pluripotent Stem Cell;Stem Cell Research - Induced Pluripotent Stem Cell - Non-Human;Transplantation;Wound Healing and Care

ORG_CITY: SHIREVIEW

ORG_NAME: KOMMODO THERAPEUTICS LLC

ORG_STATE: MN

PHR: PUBLIC HEALTH RELEVANCE Inefficient delivery of type 7 collagen (C7) to skin and mucosa limits treatment of recessive dystrophic epidermolysis bullosa (RDEB). Recent advances in non-viral genetic engineering have made it possible to engineer cells to express high levels of endogenous COL7A1, despite the large size of the COL7A1 cDNA. We will leverage this clinical stage technology to engineer a unique population of skin and mucosa resident immune cells to produce and deliver therapeutic C7 to target tissues, thus outlining a highly translational approach that is transferable to other disorders, and will lead to new discoveries to improve human health.

PI_NAMEs: SHIRKEY-SON, NICOLE J. (contact)

PROGRAM_OFFICER_NAME: WANG, XIBIN

PROJECT_TERMS: Address;Allogenic;Architecture;Area;Autologous;autosome;Body System;Bulla;Cell Therapy;Cell Transplantation;Cells;Chronic;Classification;Clinical;clinically relevant;COL7A1;Collagen;comparative;Complementary DNA;D Cells;Deposition;Dermal;design;Development;direct application;Disease;DNA Transposons;efficacy evaluation;engineered T cells;Engineering;Epidermolysis Bullosa;Epidermolysis Bullosa Dystrophica;Evaluation;experience;Failure;FDA approved;Fibroblasts;gene function;Gene Mutation;Generations;Genes;Genetic;Genetic Diseases;Genetic Engineering;genetic referral center;Genome engineering;genome-wide;Goals;graft versus host disease induction;graft vs host disease;Health;hematopoietic repopulating cell;Hematopoietic stem cells;Home;Human;Human Engineering;Immune;immunodeficiency;immunodeficient mouse model;Impairment;improved;In Vitro;in vitro testing;in vivo;Infusion procedures;Inherited;Injections;innovation;integration site;Intervention;keratinocyte;manufacturing process;Mediating;Membrane;mesenchymal stromal cell;Methods;migration;Minnesota;Morbidity - disease rate;mouse model;Mucous Membrane;Mus;Mutation;Nature;novel;novel therapeutics;Palliative Care;Pathologic;Pathology;Patients;peripheral blood;Phenotype;Physicians;Population;preclinical development;Production;Property;Proteins;public health relevance;Rare Diseases;Refractory;residence;Resolution;Safety;safety testing;Skin;Squamous cell carcinoma;Stem cell transplant;T-Lymphocyte;T-Lymphocyte Subsets;Technology;Testing;Therapeutic;therapeutic protein;Tissues;Translating;translational approach;translational potential;Translations;Treatment Efficacy;Universities;Visceral;Work;wound;Zoledronate;γδ T cells

PROJECT_TITLE: Engineered gamma delta T cells for systemic correction of dystrophic epidermolysis bullosa

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 MSOS-D (10)]


NIH_SPENDING_CATS: Aging;Arthritis;Bioengineering;Biotechnology;Chronic Pain;Osteoarthritis;Pain Research;Prevention;Regenerative Medicine

ORG_CITY: Princeton

ORG_NAME: REGENOSINE INC

ORG_STATE: NJ

PHR: Narrative Osteoarthritis (OA), a disease characterized by cartilage loss and the most common type of arthritis, affects 151 million people worldwide. Currently, there are no disease modifying OA drugs approved for treating OA in patients. The company’s solution described in this proposal is the first capable of stopping OA progression, with the potential to reverse the changes in cartilage that characterize OA through cartilage regeneration, in addition to reduction in pain and joint inflammation.

PI_NAMEs: ANGLE, SIDDHESH  (contact)

PROJECT_TERMS: Acceleration;Adenosine;Affect;Aftercare;Age;Aging;Agonist;analog;analytical method;Anatomy;Arthritis;arthropathies;Biological;Biological Availability;Biomechanics;Bone Spur;Budgets;Canis familiaris;Cartilage;cartilage regeneration;Chondrocytes;Clinical;Clinical Trials;commercialization;Consumption;Contracts;cost;Degenerative polyarthritis;Deterioration;differential expression;Disease;Disease Progression;Dose;Drug Kinetics;Engineering;Ensure;Equipment;extracellular;first-in-human;Formulation;Funding;Future;Genetic;Goals;Good Manufacturing Process;Half-Life;Harvest;health care delivery;Homeostasis;Hospitalization;improved;Inflammation;Injections;Injury;Intra-Articular Injections;joint inflammation;Joint repair;Joints;Knee;Legal patent;Life;liposomal formulation;Liposomes;Liquid substance;Magnetic Resonance Imaging;Maintenance;manufacture;manufacturing organization;manufacturing process;Medial meniscus structure;Messenger RNA;Methods;Modeling;Monitor;Morphology;Mus;National Institute of Arthritis, and Musculoskeletal, and Skin Diseases;Normal Range;novel;Obesity;Operative Surgical Procedures;Outcome;Pain;Pathogenesis;Patients;Persons;Pharmaceutical Preparations;Phase;phase 1 study;Play;Population;pre-Investigational New Drug meeting;prevent;Prevention;Process;product development;Property;Quality Control;Quality of life;radiological imaging;Rattus;Readiness;receptor;Recovery;regenerative therapy;Replacement Arthroplasty;Role;Safety;Saline;Series;Severities;Site;Small Business Innovation Research Grant;Standard Model;Sterility;sterility testing;Synovitis;Technology;Technology Transfer;Time;Toxicology;Training;Translations;Traumatic Arthropathy;trial planning;United States;United States National Institutes of Health;Validation;Whole Blood;Work

PROJECT_TITLE: Treatment and prevention of osteoarthritis with an intra-articular disease-modifying regenerative therapy

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 MCST-B (19)]


ADMINISTERING_IC: DA

IC_NAME: NATIONAL INSTITUTE ON DRUG ABUSE

NIH_SPENDING_CATS: Behavioral and Social Science;Chronic Pain;Clinical Research;Clinical Trials and Supportive Activities;Drug Abuse (NIDA only);Health Services;Opioids;Pain Research;Rural Health;Screening and Brief Intervention for Substance Misuse;Social Determinants of Health;Substance Misuse

ORG_CITY: MOUNT PLEASANT

ORG_NAME: PALMETTO INNOVATIVE EDUCATION, LLC

ORG_STATE: SC

PHR: Narrative Management of chronic pain and opioid use/misuse is challenging for clinicians and students, especially when working with diverse and underserved patient populations, and very few low-cost, flexible, highly-engaging, and effective learning resources are available to help the healthcare workforce best learn to manage these unique health concerns. Gamification holds promise as a user-friendly, fun, engaging and effective teaching strategy, especially for healthcare applications. SimuVersity Medical Center is an immersive 3D gaming platform that will engage students and practicing clinicians in a unique and captivating learning experience focused on pain and opioid management in diverse patient groups.

PI_NAMEs: BORCKARDT, JEFFREY J (contact)

PROGRAM_OFFICER_NAME: FLOOD, MORRIS

PROJECT_TERMS: 3-Dimensional;Address;Affect;chronic pain;chronic pain management;chronic pain patient;Clinical;Cognitive Therapy;common treatment;Communication;compare effectiveness;Complex;Computer software;cost;Country;Decision Making;digital;Economic Burden;Education;education resources;Educational Activities;Educational Curriculum;Educational Materials;Educational process of instructing;Effectiveness;Equipment;Ethnic Origin;experience;flexibility;Foundations;Fright;game development;Health;Health Personnel;Health Professional;health training;Healthcare;High Prevalence;higher education;improved;Individual;innovation;Knowledge;Knowledge acquisition;Laboratories;Learning;learning engagement;learning materials;learning outcome;learning strategy;Legal patent;Medical;Medical Care Team;Medical center;meetings;Modernization;motivational enhancement therapy;Nonpharmacologic Therapy;novel;Opioid;opioid tapering;opioid therapy;opioid use;Outcome;Pain;Pain management;pain relief;patient population;Patients;Persons;Phase;Productivity;Professional Practice;professional students;Provider;Race;Recommendation;Research Personnel;Resources;rural area;Schools;Scientist;screening, brief intervention, referral, and treatment;simulation;skills;socioeconomics;Standardization;student participation;Students;substance use;System;Teaching Method;Therapeutic;Training;training opportunity;treatment adherence;treatment optimization;treatment strategy;user-friendly;Video Games;virtual;Withdrawal Symptom;Woman

PROJECT_TITLE: SimuVersity Medical Center: Pain and opioid management training in diverse patient populations

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 CCHI-J (10)]


ADMINISTERING_IC: HD

IC_NAME: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT

NIH_SPENDING_CATS: Behavioral and Social Science;Bioengineering;Cardiovascular;Clinical Research;Emergency Care;Networking and Information Technology R&D (NITRD);Opioid Misuse and Addiction;Opioids;Pediatric;Physical Injury - Accidents and Adverse Effects;Substance Misuse

ORG_CITY: PROVIDENCE

ORG_NAME: NIMBUS RESEARCH LABORATORY, LLC

ORG_STATE: RI

PHR: PROJECT NARRATIVE Too many people in the US continue to die from drug overdose and penetrating trauma, and these crises are increasingly impacting adolescents. Through this NIH SBIR program, Nimbus Research Laboratory will develop, test, and implement a multi-compartment “AdvanceBox” smart storage system that provides additional rescue tools for life-threatening medical emergencies in public places such as schools so that bystanders and facility staff have rapid access to easy-to-use tools that can save lives. The AdvanceBox containers will additionally feature just-in-time rescue tool use infographics / instructions, Web links to learn- ahead videos, Web-enabled connections to layperson resuscitation training resources; 24/7/365 remote monitoring with imaging sensors, reliable networking, and electronic notifications that alert owners and managers when a container is opened or a rescue tool is used / expired; sharing of tool location and status to 9-1-1 dispatchers; and facilitated supply re-stocking.

PI_NAMEs: CAPRARO, GEOFFREY A;KOBAYASHI, LEO  (contact)

PROGRAM_OFFICER_NAME: DIXON, CINNAMON ANNE

PROJECT_TERMS: active shooter;Address;Administrator;Adolescent;age group;Antidotes;Automated External Defibrillator;boys;Breathing;Caring;Cessation of life;Characteristics;Child;Childhood;Code;Collaborations;college;commercialization;Communication;Conscious;Data;design;design verification;Development;E-learning;Economics;Education;Electronic Mail;Electronics;Emergency Department Physician;Engineering;Ensure;Event;Exercise;experience;Face;field study;girls;Goals;health communication;Health Professional;Health Technology;Hemorrhage;Hemorrhagic Shock;Hemostatic Agents;high risk population;high school;Human;Human Resources;Image;innovation;Institution;Instruction;Internet;Internet of Things;Intervention;Interview;Laboratory Research;Learning;learning materials;Life;Link;Location;manufacture;Maps;Marketing;Medical;Medical emergency;Mentors;Monitor;Multilingualism;Naloxone;Naloxone Training;New England;Notification;Opioid;opioid mortality;opioid overdose;out-of-hospital cardiac arrest;Overdose;Penetration;Persons;Pharmaceutical Preparations;Phase;Positioning Attribute;preventable death;product development;Production;programs;prototype;Readiness;remote monitoring;Resources;Resuscitation;Risk;Safety;school shooting;Schools;sensor;service programs;Services;Shapes;Site;Site Visit;Small Business Innovation Research Grant;Social Work;stem;Sterile coverings;success;System;Systems Integration;Technology;Testing;Text;Time;time use;tool;Tourniquets;Training;Training Programs;Trauma;trauma centers;Traumatic Hemorrhage;United States National Institutes of Health;user-friendly;Validation;Visit;voucher;web-enabled;Work;Workload;Youth

PROJECT_TITLE: AdvanceBox System with Networked, Monitored, and Mapped Rescue Supply Containers (Phase I)


ADMINISTERING_IC: MH

IC_NAME: NATIONAL INSTITUTE OF MENTAL HEALTH

NIH_SPENDING_CATS: Behavioral and Social Science;Brain Disorders;Clinical Research;Clinical Trials and Supportive Activities;Comparative Effectiveness Research;Complementary and Integrative Health;Depression;Mental Health;Mental Illness;Pediatric

ORG_CITY: PITTSBURGH

ORG_NAME: EQUA HEALTH, INC.

ORG_STATE: PA

PHR: NARRATIVE Young adults (aged 18-30 years) are suffering from high rates of depression, anxiety, and loneliness, and evidence-based digital treatment solutions are urgently needed. The proposed project aims to develop respiration biosignal feedback for our evidence based digital mindfulness meditation trainer (called Equa), in order to help young adults understand how they are developing their mindfulness skills. This fast track SBIR proposal offers an opportunity to develop a more engaging and evidence-based mindfulness digital trainer for curbing the growing mental health crisis in young adults.

PI_NAMEs: CRESWELL, JOHN DAVID (contact);POLOWITZ, MATHEW

PROGRAM_OFFICER_NAME: SWEENEY, MARY MARGARET

PROJECT_TERMS: Acceleration;active comparator;Address;Adult;Aftercare;aged;Anxiety;arm;Automobile Driving;Behavior Therapy;Biology;Breathing;burnout;Cellular Phone;Clinical Trials;commercialization;Communities;comparison group;Controlled Clinical Trials;cost;Data;deep learning algorithm;depressive symptoms;Diagnosis;digital;digital applications;digital treatment;Distress;Epidemic;Event;evidence base;experience;Explosion;Feedback;follow-up;Goals;haptics;improved;improved outcome;Intervention;Link;Loneliness;Marketing;Meditation;Mental Depression;Mental disorders;Mental Health;mindfulness;mindfulness meditation;Mindfulness Training;mobile application;mobile computing;Outcome;pandemic disease;Performance;Periodicity;Personal Satisfaction;Phase;Physiological;Pilot Projects;Placebo Control;Populations at Risk;Positioning Attribute;programs;Psyche structure;randomized placebo controlled trial;Relapse;Research;research and development;Respiration;response;Risk Factors;Risk Reduction;Sampling;satisfaction;signal processing;Signal Transduction;skill acquisition;skills;Small Business Innovation Research Grant;Stress;stress management;Suicide;symptomatology;System;Technology;Testing;three-arm clinical trial;Time;tool;Training;Translating;trial comparing;university student;usability;Visualization;Work;young adult

PROJECT_TITLE: Mindfulness Meditation and Respiration Biosignal Feedback

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 BP-C (10)]


NIH_SPENDING_CATS: Bioengineering;Biotechnology;Digestive Diseases;Prevention;Wound Healing and Care

ORG_CITY: Cambridge

ORG_NAME: BIODEVEK INC

ORG_STATE: MA

PHR: Gastrointestinal bleeding is a life-threatening condition that affects millions of American citizens every year, resulting in half a million hospitalizations and more than five billion dollars in direct costs. While current solutions cannot prevent post-operative bleeding and are difficult to use, BioDevek has developed GastroShield, an easy-to-use hydrogel-based sealant that can be endoscopically administered to seal post-operative lesions with high risk of bleeding, achieving high levels of adhesion to the mucosal tissue. Following obtaining critical milestones confirming the safety and pilot efficacy of the technology, this grant will allow BioDevek to initiate scale up manufacturing, develop quality control systems, and obtain comprehensive pre-clinical results that will integrate GastroShield data package for FDA regulatory submission.

PI_NAMEs: MUNOZ TABOADA, GONZALO  (contact)

PROGRAM_OFFICER_NAME: LUNSFORD, DWAYNE

PROJECT_TERMS: Acids;Acute;Address;Adhesions;Adhesives;Affect;American;Amines;animal efficacy;Biocompatible Materials;biodegradable polymer;biomaterial compatibility;Catheters;Chronic;chronic wound;Clip;commercialization;crosslink;cytotoxicity;Data;design;Development;Devices;Dextrans;Direct Costs;efficacy study;efficacy testing;Ensure;Equipment;Excision;Family suidae;Formulation;gastrointestinal;Gastrointestinal Diseases;Gastrointestinal Hemorrhage;Gastrointestinal Neoplasms;genotoxicity;Goals;Grant;Guidelines;hemocompatibility;Hemorrhage;Hemostatic Agents;Hemostatic function;high risk;Hospitalization;Hydrogels;implantation;In Vitro;in vivo;in vivo Model;Instruction;Intervention;invention;irritation;Laceration;large scale production;Length of Stay;Lesion;Life;manufacture;manufacturing process;manufacturing quality;manufacturing scale-up;Mechanics;Medical Device;meetings;metallicity;Methods;Modeling;Mucous Membrane;novel;Operative Surgical Procedures;Patients;Performance;Phase;Poloxamers;Polymers;Polypectomy;Polyps;porcine model;Postoperative Hemorrhage;Postoperative Period;Powder dose form;pre-clinical;Pre-Clinical Model;preclinical development;preclinical efficacy;preclinical study;prevent;Prevention;Process;Production;Quality Control;Regulatory Pathway;Reporting;research and development;Safety;safety study;seal;sealant;skills;Specific qualifier value;subcutaneous;Submucosa;System;Technology;technology validation;Testing;Toxic effect;Validation;Work;wound

PROJECT_TITLE: Production of a Hydrogel-based Mucosal Sealant for Gastrointestinal Bleeding Prevention

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 KUDS-R (10)]


ADMINISTERING_IC: GM

IC_NAME: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

NIH_SPENDING_CATS: Biotechnology

ORG_CITY: MADISON

ORG_NAME: BELLBROOK LABS, LLC

ORG_STATE: WI

PHR: Narrative High throughput enzyme assays are a critical tool for targeted drug discovery, and the unavailability of robust assays for some emerging target families is slowing discovery of new drugs across therapeutic areas. We are proposing to develop chemically-induced dimerization domains for key metabolites such as coenzyme A as a platform for generic assays for histone acetyltransferases and other emerging target families.

PI_NAMEs: LOWERY, ROBERT G (contact)

PROGRAM_OFFICER_NAME: CHO, THOMAS Y

PROJECT_TERMS: Acceleration;Acetyl Coenzyme A;Affinity;Antibodies;Area;assay development;Binding;Binding Proteins;Biological Assay;biophysical techniques;candidate selection;Carbon;Cardiovascular Diseases;Chemicals;Coenzyme A;cofactor;Complex;Detection;detection limit;Development;Dimerization;drug discovery;Drug Targeting;Enzyme Inhibition;Enzymes;Epigenetic Process;Escherichia coli;Family;flexibility;Fluorescence;Fluorescence Resonance Energy Transfer;high throughput screening;histone acetyltransferase;Histone Deacetylase;histone demethylase;Histones;In Vitro;inhibitor;Investigation;Label;Lead;Libraries;Ligand Binding;Ligands;Malignant Neoplasms;Messenger RNA;meter;Methods;Molecular Conformation;molecular recognition;nanomolar;Nervous System Disorder;novel therapeutics;Nucleotides;O-Acetyl-ADP-Ribose;Pharmaceutical Preparations;Phase;phosphoric diester hydrolase;Phosphotransferases;prevent;Process;Property;Proteins;Publishing;Randomized;Reaction;Reagent;response;Review Literature;screening;Sensitivity and Specificity;Sirtuins;small molecule;Succinates;System;Testing;Therapeutic;therapeutic target;Time;tool;Validation;virtual

PROJECT_TITLE: Chemically Induced Dimerization Systems for High Throughput Enzyme Assays

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 MBBC-G (10)]


NIH_SPENDING_CATS: Cancer;Cervical Cancer;Clinical Research;Clinical Trials and Supportive Activities;Infectious Diseases;Prevention;Rare Diseases;Sexually Transmitted Infections;Women's Health Research

ORG_CITY: TRUMBULL

ORG_NAME: GYNION, LLC

ORG_STATE: CT

PHR: PROJECT NARRATIVE Up to 1 million women are diagnosed with CIN each year in the US. Current therapeutic options have clinical limitations and are not available for immediate use resulting in treatment delays or no treatment at all. To address this issue, Gynion is developing Clarablex, a topical gel that will be an affordable and effective solution to safely and consistently eradicate CIN lesions in the office setting as soon as the woman is diagnosed and thus prevent cervical cancer.

PI_NAMEs: SHIKHMAN, OLEG UNITED STATES (contact)

PROGRAM_OFFICER_NAME: REGMI, SAROJ GOPAL

PROJECT_TERMS: Ablation;Abnormal Cell;Accidents;Address;Affect;Aftercare;Anatomy;Area;attributable mortality;black women;Cancer Burden;Capital;Cell Proliferation;Cervical;Cervical Cancer Screening;Cervical Intraepithelial Neoplasia;Cervix Neoplasms;Cervix Uteri;Characteristics;Chemicals;Chemistry;Clinical;Clinical Trials;Cold Therapy;Collaborations;Conization;cost;cost effective;design;Development;Devices;Diagnosis;Effectiveness;Electrosurgery;Endocervix;Environment;Equipment;Excision;Exocervix;experience;experimental study;Extravasation;Formalin;Formulation;Gases;Gel;Gossypium;Gynecologist;Health Personnel;healthcare burden;Histologic;Hour;Human;Human Papillomavirus;Hysterectomy;improved;Informed Consent;Lead;Left;Lesion;Logistics;low and middle-income countries;Malignant neoplasm of cervix uteri;Malignant Neoplasms;manufacture;Measures;Methods;Modeling;Necrosis;neoplastic;obstetric outcomes;Oncogenic;Operating Rooms;Operative Surgical Procedures;optimal treatments;Penetration;Pharmaceutical Preparations;Phase;phase 1 study;point of care;Pregnancy;premalignant;Premature Birth;Preparation;prevent;Procedures;professor;Provider;Randomized;Recommendation;Reliability of Results;Reproductive Tract Infections;Research;Risk;Safety;safety study;Saline;Schedule;screening;Screening for cancer;Sexual Transmission;skills;Small Business Innovation Research Grant;Specimen;Surface;Swab;Syringes;Technology;Therapeutic;Time;Tissues;Topical application;Toxicology;Training;treatment duration;treatment strategy;Trichloroacetic Acid;Universities;Uterus;Vaccination;Vaginal delivery procedure;Virus Diseases;Viscosity;Visit;Water;Woman;women's diagnosis;World Health Organization

PROJECT_TITLE: Development of ablative therapy for the destruction of cervical neoplasia

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 EMS-S (10)]


NIH_SPENDING_CATS: Aging;Assistive Technology;Bioengineering;Biomedical Imaging;Clinical Research;Clinical Trials and Supportive Activities;Neurosciences;Physical Injury - Accidents and Adverse Effects;Prevention;Rehabilitation

ORG_CITY: NORTH BETHESDA

ORG_NAME: WEINBERG MEDICAL PHYSICS, LLC

ORG_STATE: MD

PHR: Narrative Older adults often have alterations in the brain balance circuit that cause ineffective responses to prevent a fall when balance is challenged. In this proposal, we present early data from human studies in which transcranial magnetic stimulation (TMS) was guided by magnetic resonance imaging [MRI] and electroencephalography [EEG] to focus on the supplementary motor area in elderly subjects with balance disorders. These data show that the balance-circuit activation patterns in those elderly patients changed to patterns resembling young healthy subjects, and that short-term balance was improved (long-term balance was not evaluated). Our aim in the proposed Phase I project is to conduct a more comprehensive clinical study of these guided TMS methods in the treatment of balance deficits in elderly patients with a history of falls.

PI_NAMEs: PARIKH, PRANAV J (contact)

PROGRAM_OFFICER_NAME: ST  HILLAIRE-CLARKE, CORYSE

PROJECT_TERMS: Absence of pain sensation;Adverse effects;adverse outcome;Affect;Alzheimer's Disease;Area;Brain;brain abnormalities;brain circuitry;Capital Expenditures;Clinic;Clinical;Clinical Research;Collaborations;commercialization;Communities;Compensation;Contralateral;Data;Dendritic Spines;Devices;Double-Blind Method;Elderly;Electroencephalography;equilibration disorder;Equilibrium;Exercise;experience;fall injury;Fall prevention;fall risk;falls;fear of falling;Financial Hardship;foot;functional decline;Generations;Glutamates;handheld mobile device;Hip Fractures;Home;Hospitalization;Human;human data;human old age (65+);improved;Injury;Intervention;Location;Long-Term Potentiation;Magnetic Resonance Imaging;magnetic resonance imaging/electroencephalography;Measures;Mediating;Medical center;Methods;Motor;Multiple Sclerosis;Nervous System Disorder;Neurologic;Neuronal Plasticity;Neuropathy;Nursing Homes;older adult;older patient;Otolaryngology;Parkinson Disease;Patients;Pattern;Performance;Persons;Pharmaceutical Preparations;Phase;Physical Exercise;Pilot Projects;Population;prevent;prospective;Public Health;Quality of life;Randomized;Recording of previous events;Recovery Support;Regimen;repaired;repetitive transcranial magnetic stimulation;Research Personnel;response;Rest;Risk Reduction;Rotation;satisfaction;Schizophrenia;Science;social;Stroke;stroke patient;Structure;Synapses;System;Technology;Transcranial magnetic stimulation;Traumatic Brain Injury;Traumatic injury;United States Food and Drug Administration;Urology;Walking;Work

PROJECT_TITLE: Treating Balance Impairment of the Elderly with TMS-induced Brain Connectivity

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 NV-H (13)]


ADMINISTERING_IC: OH

IC_NAME: NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH

ORG_CITY: MINNEAPOLIS

ORG_NAME: INNOVATIVE DESIGN LABS, INC.

PHR: Project Narrative Musculoskeletal disorders are a group of painful disorders of soft tissues (i.e., muscles, tendons, nerves, joints, cartilage, and ligaments). Despite the ongoing mechanization of manual labor, work-related musculoskeletal disorders are highly prevalent and costly in industrialized countries, causing sufferers significant personal, social, and economic pain. In the US, over 4.5 million work-related injuries occur per year, accounting for 104 million lost production days.

PI_NAMEs: KABLAN, JOHN  (contact)

PROGRAM_OFFICER_NAME: CHIOU, SHARON

PROJECT_TITLE: Active Arm-Support Industrial Exoskeleton to Reduce Work-Related Musculoskeletal Disorders (WRMSDs)

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 MSOS-A (11)]


ADMINISTERING_IC: MD

IC_NAME: NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES

NIH_SPENDING_CATS: Behavioral and Social Science;Clinical Research;Clinical Trials and Supportive Activities;Comparative Effectiveness Research;Data Science;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Health Services;Prevention;Social Determinants of Health;Telehealth

ORG_CITY: DURHAM

ORG_NAME: ONE COW STANDING, LLC

ORG_STATE: NC

PHR: PROJECT NARRATIVE Recent advances in data science present a salient opportunity to create resources that accelerate and improve the process of developing digital health interventions and empower intervention developers to better address diverse real-world needs and deliver health-promoting activities across at-risk populations. We propose to refine and evaluate HMP Next Gen, a comprehensive, evidence-based digital health solution poised to expedite culturally meaningful research to promote health equity. If successful, HMP Next Gen will reduce research costs and management burden, by expediting study start-up and implementation.

PI_NAMEs: BUCKNER, NICKIE  (contact);HIGHTOW-WEIDMAN, LISA B

PROGRAM_OFFICER_NAME: BARKSDALE, CRYSTAL

PROJECT_TERMS: Acceleration;acceptability and feasibility;Address;AIDS prevention;Artificial Intelligence;Behavior;behavior change;Behavioral;Behavioral Sciences;career;Caring;Clinical Trials;cloud based;Communities;community based research;Computer software;Continuity of Patient Care;cost;Data Science;data visualization;design;Development;digital;digital health;effective intervention;empowerment;Ensure;evidence base;Evidence based intervention;experience;Face;Feedback;Funding;Future;Goals;Health;health disparity;Health education;health equity promotion;health management;Health Promotion;health seeking behavior;Health Services Accessibility;HIV;HIV risk;human centered design;improve minority health;improved;Incidence;Individual;Inequity;innovation;Intervention;Intervention Studies;Logistics;Mental Health;minority investigator;mobile computing;Modernization;multi-component intervention;National Institute on Minority Health and Health Disparities;operation;Outcome;Participant;patient engagement;Phase;Population;Populations at Risk;Process;process improvement;Public Health;Research;Research Personnel;Research Project Grants;Resources;response;Risk Behaviors;Risk Reduction;Running;satisfaction;Science;Self Management;Services;Shapes;skills;social;social stigma;Social support;software development;System;Technology;Time;tool;transmission process;Underrepresented Minority;underserved community;usability;user-friendly;Visualization;Work

PROJECT_TITLE: The HMP Next Gen digital health platform: accelerating research implementation, amplifying public health impact

STUDY_SECTION_NAME: Special Emphasis Panel[ZMD1 JT (J1)]


NIH_SPENDING_CATS: Kidney Disease

ORG_CITY: LITTLE ROCK

ORG_NAME: NEPHSMART LLC

ORG_STATE: AR

PHR: Narrative It is difficult to predict which patients will progress to severe acute kidney injury but a test that can make that prediction would be clinically valuable. In this study we will develop a test that can predict the development of severe acute kidney injury and test its accuracy.

PI_NAMEs: ARTHUR, JOHN M. (contact)

PROGRAM_OFFICER_NAME: GOSSETT, DANIEL ROBERT

PROJECT_TERMS: Acute Renal Failure with Renal Papillary Necrosis;Amino Acids;Biological Assay;Biological Markers;Biotinylation;C-terminal;Cardiac Surgery procedures;Chronic Obstructive Pulmonary Disease;Clinical;Clinical Trials;comorbidity;Critical Care;Critical Illness;Data;Detection;Development;Devices;Diabetes Mellitus;Dialysis procedure;drug development;Early Diagnosis;Encephalopathies;Enrollment;enzyme activity;Enzymes;Future;Goals;Heart failure;Hypertension;IGFBP1 gene;improved;improved outcome;Infective endocarditis;Label;Lateral;lateral flow assay;liver transplantation;Lupus;Malignant Neoplasms;Measures;Monitor;N-terminal;nanoGold;novel therapeutics;Operative Surgical Procedures;Patient Care;Patients;Peptides;Pharmacotherapy;Phase;Physicians;Pneumonia;point of care testing;Program Development;Proteins;Proteolysis;Proteomics;Reagent;Renal dialysis;Risk;Sampling;Seizures;Sepsis;Site;Small Business Technology Transfer Research;Specimen;Surgeon;synthetic peptide;Temperature;Testing;tool;Trauma;treatment response;Urine;Visualization;Western Blotting

PROJECT_TITLE: A Device for Detection of Acute Kidney Injury

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 KUDS-R (11)]


ORG_CITY: Middleton

ORG_NAME: VARIGEN BIOSCIENCES CORPORATION

PHR: Project Narrative. Discovery of natural product modulators of RNA splicing has provided an opportunity for a chemical biology-based interrogation of the RNA splicing processes and for new therapeutic approaches to cancer. Here we provide a path to production of complex polyketides that modulate the spliceosome for anticancer drug discovery and development through a program that combines the strengths of medicinal chemistry with synthetic biological engineering and production.

PI_NAMEs: BURKART, MICHAEL D.;EUSTAQUIO, ALESSANDRA S;MEAD, DAVID ALAN (contact)

PROGRAM_OFFICER_NAME: LOU, XING-JIAN

PROJECT_TERMS: Acute Myelocytic Leukemia;Alkenes;Anabolism;analog;anti-cancer therapeutic;Antineoplastic Agents;Architecture;Biology;Biomedical Engineering;Chemicals;Clinical;clinical translation;Clinical Trials;clinically relevant;Complex;cost;cost effective;Credentialing;CRISPR/Cas technology;Data;design;diene;drug development;drug discovery;Engineering;Enzymes;epoxidase;Evaluation;feeding;flexibility;Future;Gene Cluster;Genes;Genomics;Goals;Hand;improved;in vivo;Lead;Length;Life;Malignant Neoplasms;manufacture;manufacturing cost;manufacturing scale-up;Medicine;member;Methods;Methylation;Methyltransferase;Molecular;Natural product discovery;natural product inspired;Natural Products;next generation;novel;novel therapeutic intervention;Organism;Pharmaceutical Chemistry;Phase;Phase I Clinical Trials;polyketide synthase;polyketides;pre-clinical;prevent;Process;Production;programs;Proteins;Reporting;Research;research clinical testing;RNA Splicing;small molecule;small molecule therapeutics;Spliceosomes;Streptomyces;Streptomyces lividans;Structure;success;synthetic biology;System;targeted cancer therapy;Testing;thioester;tool;U2 Small Nuclear Ribonucleoprotein;Variant

PROJECT_TITLE: Synthetic Biology for Splice Modulating Polyketides


ADMINISTERING_IC: HL

IC_NAME: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

NIH_SPENDING_CATS: Assistive Technology;Bioengineering;Cardiovascular;Congenital Heart Disease;Congenital Structural Anomalies;Heart Disease;Infant Mortality;Lung;Pediatric;Rare Diseases

ORG_CITY: San Diego

ORG_NAME: STARLIGHT CARDIOVASCULAR, INC.

ORG_STATE: CA

PHR: PROJECT NARRATIVE Many babies born with Congenital Heart Disease (CHD) require surgical intervention within days of life to survive. Surgery is invasive and can require putting the baby on a heart-lung bypass machine, which can have negative consequences. Starlight Cardiovascular will develop the first branch pulmonary artery flow restrictors designed specifically for babies with CHD that can be delivered minimally-invasively through a catheter, which could replace surgery and improve patient outcomes with an increased safety profile.

PI_NAMEs: TANG, BEVERLY  (contact)

PROGRAM_OFFICER_NAME: BURNS, KRISTIN

PROJECT_TERMS: Acute;Address;Adult;aged;Anatomic Models;Animal Testing;Animals;Arteries;Beds;Blood flow;Blood Platelets;Blood Vessels;Boston;Cardiopulmonary Bypass;Cardiovascular system;care costs;Catheters;Childhood;Chronic;Circulation;Clinical;Clinical Research;commercialization;Communication;Computer Models;congenital heart abnormality;design;Development;Device Designs;Device or Instrument Development;Devices;Equilibrium;Family suidae;FDA approved;Femoral vein;Freezing;Grant;Growth;Hand;heart defect;Histology;Hypoplastic Left Heart Syndrome;Implant;implant design;implantable device;implantation;improved;innovation;interest;Intervention;Label;Length;Life;Lung;Marketing;Mechanics;Medical Device;Methods;migration;minimally invasive;Modeling;Modification;neonatal patient;neonatal surgery;neonate;Newborn Infant;Operative Surgical Procedures;Outcome;Pathology;Patient-Focused Outcomes;Pediatric Hospitals;Perforation;Performance;Phase;Physicians;Physiological;porcine model;pre-clinical;Preparation;Procedures;Pulmonary Artery Branch;Pulmonary artery structure;repaired;Research;Resistance;Rest;Risk;Safety;Small Business Innovation Research Grant;stability testing;success;Surgeon;Surgical sutures;Testing;Thoracic Surgical Procedures;thrombogenesis;Thrombosis;Truncus Arteriosus;United States;Ventricular Septal Defects;verification and validation

PROJECT_TITLE: DEVELOPMENT OF A PULMONARY FLOW RESTRICTOR FOR HYPOPLASTIC LEFT HEART SYNDROME

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 ISB-W (12)]


NIH_SPENDING_CATS: Antimicrobial Resistance;Biodefense and Related Countermeasures;Complementary and Integrative Health;Emerging Infectious Diseases;Infectious Diseases;Machine Learning and Artificial Intelligence;Natural Products;Networking and Information Technology R&D (NITRD)

ORG_NAME: CHEMIA BIOSCIENCES, INC.

PHR: Project Narrative In the United States, antibiotic-resistant pathogens infect over a million and kill more than 23,000 patients each year. The national direct healthcare cost of antibiotics resistance is $20 Billion per year, while the loss of productivity is estimated to cost $35 billion annually. This project creates a service for high-throughput discovery of natural products drug leads with activity against ESKAPE pathogens that are not toxic to healthy human cell lines.

PI_NAMEs: BEHSAZ, BAHAR  (contact)

PROGRAM_OFFICER_NAME: ASLAN, KADIR

PROJECT_TERMS: Active Sites;adenylate;Amino Acids;Anabolism;Anti-Bacterial Agents;anti-cancer;anti-fungal agents;Antibiotic Resistance;Antibiotics;Bacteria;Bacterial natural products;Benchmarking;Biochemical Reaction;Biological Sciences;Chemicals;Chemistry;Cholesterol;Clinical;Cloud Service;commercial application;Computer Analysis;Computing Methodologies;cost;cost effective;Cyclosporins;Data;Databases;drug development;drug resistant pathogen;effective therapy;Enzymes;ESKAPE pathogens;foodborne illness;Fractionation;Fungal Genome;Fungal natural products;fungus;Gene Cluster;Genes;Genome;Goals;Gonorrhea;Health Care Costs;High Pressure Liquid Chromatography;Human Cell Line;Immunosuppressive Agents;Infection;Letters;Licensing;Lovastatin;machine learning method;Marketing;Mass Spectrum Analysis;Medicine;Methods;microbial;microbial genome;Microbial natural product;microbial products;microorganism;Mining;Modernization;Modification;Molecular;monomer;natural antimicrobial;Natural Extract;Natural product discovery;Natural Product Drug;Natural Products;novel;Organism;Paclitaxel;pathogen;Pathogenicity;Patients;Penicillins;peptide structure;Peptides;Pharmaceutical Preparations;Phenotype;Pneumonia;pre-clinical;prediction algorithm;Process;productivity loss;programs;protein complex;Public Health;recruit;Research Personnel;Running;screening;Septicemia;Services;small molecule;software development;Structure;success;Techniques;Technology;text searching;Therapeutic;Time;Toxic effect;training data;Tuberculosis;United States;Validation;Variant;World Health Organization

PROJECT_TITLE: Discovering novel natural products from fungal species


ADMINISTERING_IC: EB

IC_NAME: NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING

NIH_SPENDING_CATS: Bioengineering;Clinical Research;Clinical Trials and Supportive Activities;Pain Research;Physical Injury - Accidents and Adverse Effects;Wound Healing and Care

ORG_CITY: NAPLES

ORG_NAME: GLOBAL BIOMEDICAL TECHNOLOGIES, LLC

ORG_STATE: FL

PHR: Narrative – Negative pressure wound therapy (NPWT) has become a common primary or adjunctive treatment approach for more than 100 indications, including chronic complex wounds that are potentially non-healing, and acute open wounds that are infected or subject to swelling, severe burns, and post operative care. Despite demonstrated benefits of NPWT, the technology faces challenges regarding the adhesive sealant component of the system as the strong adhesive required to establish and maintain an airtight seal for successful implementation of NPWT substantially increases the chances for mechanical injury. Addressing this, Global Biomedical Technologies proposes to develop an adhesive NPWT drape with an innovative “switchable adhesive” technology for painless and trauma free removal and replacement.

PI_NAMEs: ROSING, HOWARD  (contact);WINCHELL, ROBERT JOHN

PROGRAM_OFFICER_NAME: ASHMONT, KARI RICH

PROJECT_TERMS: Acrylates;Acute;Acute Pain;Address;Adherence;Adhesions;Adhesives;Alcohols;Analgesics;Bandage;biomaterial compatibility;Biomedical Engineering;Biomedical Technology;Burn injury;Chronic;chronic wound;Client satisfaction;Complex;Data;Dermis;Devices;Discipline of Nursing;economic value;Effectiveness;elastomeric;Elastomers;Enrollment;Esters;Ethanol;Excision;Exhibits;experience;Exudate;Face;Glycerol;healing;Hospitals;Impaired wound healing;improved;Incidence;Indiana;Injury;innovation;inpatient surgery;Intervention;Isopropanol;Legal patent;Marketing;Measures;Mechanics;Medical;Medical center;medical specialties;Molecular Weight;novel;Oligonucleotides;open wound;Operative Surgical Procedures;Pain;pain scale;Painless;Patients;Performance;Phase;poly(glycerol-sebacate);polyacrylate;Porifera;Postoperative Care;Postoperative Period;Predisposition;Presbyterian Church;pressure;Process;Randomized;Randomized, Controlled Trials;Research Personnel;Risk;seal;sealant;severe burns;Site;Skin;skin damage;Skin injury;skin irritation;skin wound;Sterile coverings;Stress;Swelling;System;Technology;Time;Tissues;Trauma;treatment duration;Vacuum;wound;wound bed;wound care;Wound Infection;wound treatment

PROJECT_TITLE: Surgical drape with a releasable acrylic adhesive for atraumatic negative pressure wound therapy

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 ISB-S (11)]


NIH_SPENDING_CATS: Aging;Behavioral and Social Science;Bioengineering;Brain Disorders;Clinical Research;Clinical Trials and Supportive Activities;Eye Disease and Disorders of Vision;Neurodegenerative;Neurosciences;Parkinson's Disease

ORG_CITY: CHARLOTTESVILLE

ORG_NAME: BARRON ASSOCIATES, INC.

ORG_STATE: VA

PHR: Project Narrative The objective of the proposed work is to develop the intelligent, easy-to-use, unobtrusive ParkinSense system to assist PD patients with freezing of gait symptoms by providing an optimal, personalized cueing strategy. The proposed system will improve quality of life for patients that suffer from FOG by reducing both the incidence of FOG and the duration of FOG episodes through its multimodal, individualized, and adaptive smart cueing capability. The unobtrusiveness of the ParkinSense system, its wide range of cue varieties, and its ability to automatically detect FOG and provide the exact type of cues that are most effective, will be appealing, practical, and efficacious compared to existing systems.

PI_NAMEs: CLARK, BRIAN R (contact)

PROJECT_TERMS: Address;Adherence;Admission activity;Adult;Affect;Age;Algorithms;American;Auditory;Bluetooth;Calibration;Chronic;Clinical;Clinical Trials;Cognitive;Communities;Computer software;Cues;Custom;Data;debilitating symptom;design;Detection;Devices;disability;Distress;Emotional;Evaluation;Event;experience;Eyeglasses;fall injury;flexibility;foot;Freedom;Freezing;Frequencies;Fright;Functional disorder;Gait;Goals;Head;Health Personnel;Health Status;Home;Home environment;Hospitalization;improved;Incidence;Individual;instrument;Intention;Intervention;Laboratories;Leg;light weight;Limb structure;Link;Manuals;Marketing;Methods;Monitor;Motor;motor symptom;Movement Disorders;multimodality;Music;Nature;Neurodegenerative Disorders;Newly Diagnosed;novel;Nursing Homes;Operative Surgical Procedures;Outcome;Parkinson Disease;Patients;Periodicity;Persons;Pharmaceutical Preparations;Pharmacological Treatment;Phase;phase 1 study;phase 2 study;Population;Prevalence;prevent;programs;Protocols documentation;prototype;Public Health;Quality of life;randomized, clinical trials;Reporting;Research;Research Design;response;Small Business Innovation Research Grant;social;Specificity;Speech;Symptoms;System;Tactile;Technology;Thinness;Time;usability;verbal;Visual;Visual Fields;Walking;wearable device;wireless;Work

PROJECT_TITLE: A Novel Instrument to Address Freezing of Gait in Parkinson's Patients

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 NV-C (10)]


ADMINISTERING_IC: NS

IC_NAME: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

NIH_SPENDING_CATS: Bioengineering;Biomedical Imaging;Brain Disorders;Cerebrovascular;Clinical Research;Neurosciences;Physical Injury - Accidents and Adverse Effects;Stroke;Traumatic Head and Spine Injury

ORG_CITY: NEW YORK

ORG_NAME: NEURALENZ, INC

ORG_STATE: NY

PHR: NARRATIVE Stroke is a leading cause of death and debilitation in the United States, affecting nearly 800,000 people each year. Currently, stroke diagnosis and treatment is dependent on advanced imaging tests; however, lack of prompt diagnosis for ischemic stroke results in less than 4% of U.S. patients receiving thrombolytic therapy. There is no currently available clinically effective method to measure these factors rapidly, continuously, quantitatively, and non-invasively. To address this critical need, Neuralenz is developing an integrated platform permitting rapid, non-invasive, real-time measurement of critical factors used to diagnose and guide treatment for stroke patients.

PI_NAMEs: KHOLIQOV, OYBEK  (contact)

PROGRAM_OFFICER_NAME: AUBRECHT, TARYN GRACE

PROJECT_TERMS: absorption;Accounting;Acute;Address;Adult;Affect;Aftercare;Age;Alteplase;Anatomy;Blood flow;Brain;Brain hemorrhage;Calibration;Caring;Cause of Death;cerebral blood volume;Cerebral perfusion pressure;Cerebrovascular Circulation;Clinical;Clinical Research;cohort;Collection;Computer software;Coupling;cranium;Data;Development;Devices;Diagnosis;diagnostic biomarker;diagnostic screening;Dimensions;Disease;Exclusion Criteria;Fiber;Gender;Gold;Head;Hemorrhage;Hour;Human;human subject;Image;in vivo;indexing;Individual;Intervention;Intracranial Pressure;Ischemia;Ischemic Stroke;Left;Light;Link;Magnetic Resonance;Magnetic Resonance Imaging;Measurement;Measures;Methods;Monitor;Near-Infrared Spectroscopy;Nervous System Disorder;neural;Noise;novel;Optical Methods;optical sensor;Optics;Outcome;Oxygen;parallelization;Patients;Perfusion;Persons;Phase;phase 1 study;Photons;point-of-care diagnosis;pressure;Property;real time monitoring;Recovery;Risk;Risk Factors;Scalp structure;Signal Transduction;Specificity;stem;Stroke;stroke patient;stroke symptom;stroke therapy;Structure;System;Techniques;Technology;temporal measurement;Testing;Thick;thrombolysis;Thrombolytic Therapy;Time;Traumatic Brain Injury;United States

PROJECT_TITLE: Development of highly parallelized interferometric near-infrared spectroscopy for the real-time non-invasive measurement of cerebral blood flow

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 ISB-Z (10)]


NIH_SPENDING_CATS: Acquired Cognitive Impairment;Aging;Alzheimer's Disease Related Dementias (ADRD);Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD);Amyotrophic Lateral Sclerosis (ALS);Brain Disorders;Dementia;Frontotemporal Dementia (FTD);Neurodegenerative;Neurosciences;Orphan Drug;Rare Diseases

ORG_CITY: BALTIMORE

ORG_NAME: REZIGENE, LLC

PHR: Project Narrative Protein quality control is a fundamental system in the cell that is important for normal cellular functions and defense against potential pathogenic insults. Protein misfolding and aggregation are a central feature of many neurodegenerative diseases including Alzheimer’s disease (AD), frontotemporal dementia (FTD), and amyotrophic lateral sclerosis (ALS). The studies in this proposal will evaluate a novel proteotoxicity-suppressing target and the pharmacological agents to boost protein quality control in models of neurodegenerative diseases.

PI_NAMEs: ZHANG, TAO  (contact)

PROGRAM_OFFICER_NAME: GILCHRIST, FLOY ANNETTE

PROJECT_TERMS: Address;age related neurodegeneration;Alzheimer's Disease;Amyotrophic Lateral Sclerosis;amyotrophic lateral sclerosis therapy;Animal Model;Binding Proteins;Biochemical;Biological;C9ORF72;Cell Physiology;Cell Reprogramming;Cells;Clinical;Collaborations;commercialization;Data;Dementia;design;Development;Dipeptides;Disease;drug candidate;Drug Kinetics;effective therapy;efficacy evaluation;Evaluation;Frontotemporal Dementia;frontotemporal lobar dementia amyotrophic lateral sclerosis;Genetic;genetic regulatory protein;Goals;Heat-Shock Response;Human;Huntington Disease;In Vitro;in vivo;Induced pluripotent stem cell derived neurons;inhibitor;innovation;Innovative Therapy;insight;Intervention;Knowledge;L3MBTL1 gene;Legal patent;Licensing;Link;Malignant neoplasm of brain;Mediation;Medicine;Modeling;Molecular Target;Motor Neurons;mouse model;Muscular Atrophy;mutant;Nerve Degeneration;Neurodegenerative Disorders;neuron loss;Neurons;new therapeutic target;novel;novel therapeutic intervention;novel therapeutics;Paralysed;Parkinson Disease;Pathogenesis;Pathogenicity;Pathologic;Pathway interactions;Patients;Pharmaceutical Preparations;pharmacologic;Phase;phase 2 study;phase II trial;Play;preclinical study;prevent;Prion Diseases;programs;Property;protective effect;protein aggregation;protein misfolding;Proteins;proteostasis;proteotoxicity;Quality Control;Research;Respiratory Failure;response;Role;Safety;screening;Small Business Technology Transfer Research;small molecule;small molecule inhibitor;Stress;superoxide dismutase 1;System;Technology;Testing;Therapeutic Agents;Universities;Work

PROJECT_TITLE: Developing an Anti-proteotoxicity Therapy for Neurodegenerative Diseases

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 AN-P (11)]


ADMINISTERING_IC: AI

IC_NAME: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

ORG_CITY: St. Paul

ORG_NAME: MARPAM PHARMA, LLC

PHR: PROJECT NARRATIVE MarPam Pharma is developing a chimeric antigen receptor (CAR)-T cell treatment that targets HIV viral reservoirs for durable remission of HIV, thus addressing a critical unmet medical need for people living with HIV. To develop an in vivo produced CAR-T cell product, this proposal seeks to perform the necessary in vitro proof-of-concept studies of generating and assessing receptor-targeted, adeno-associated virus-directed production of CAR-T cells that kill HIV-producing cells in viral reservoirs. This study lays the groundwork not only for developing in vivo produced HIV CAR-T cell therapeutics, but also for other therapeutic areas that could benefit from in vivo production of CAR-T cells.

PI_NAMEs: ATHANASIOU, MARIA CONSTANCE (contact);SCHMIDT, DANIEL

PROGRAM_OFFICER_NAME: SANDERS, BRIGITTE E

PROJECT_TERMS: Address;adeno-associated viral vector;Allogenic;Antibodies;antiretroviral therapy;Area;Autologous;B-Lymphocytes;Back;Binding;BLR1 gene;CAR T cell therapy;CD8-Positive T-Lymphocytes;cell killing;cell motility;Cell surface;Cell Survival;Cells;Characteristics;chemokine receptor;chimeric antigen receptor;chimeric antigen receptor T cells;chronic infection;comparison control;Complex;cost;CXCL13 gene;Cytotoxic T-Lymphocytes;Dependovirus;Devices;Disease remission;DNA;Encapsulated;Engineering;expectation;FDA approved;Future;Gene Delivery;gene delivery system;gene therapy;Generations;Genetic Identity;HIV;HIV resistance;HIV therapy;HIV-1;Home;Homing;Human;Immune;In Vitro;in vitro Assay;in vivo;Individual;Infusion procedures;Intellectual Property;Leukapheresis;Ligands;Lymphoid;Lymphoid Tissue;Macaca mulatta;Malignant Neoplasms;Medical;Memory;Methods;Modeling;Monoclonal Antibodies;Morbidity - disease rate;mortality;nanoparticle;nonhuman primate;novel;Oncology;particle;Patients;Peripheral Blood Mononuclear Cell;Persons;Phase;Phenotype;Process;Production;Protocols documentation;Public Health;receptor;Regimen;Reporting;RNA;Safety;Site;SIV;success;T cell therapy;T-Cell Receptor Therapy;T-Lymphocyte;targeted treatment;Technology;Therapeutic;therapy adherence;Transmission Electron Microscopy;Tropism;United States;vector;Viral;Viral Load result;Viral Physiology;Viral reservoir;viral RNA;viral transmission;Virus;Virus Replication;Western Blotting

PROJECT_TITLE: Proof of concept studies for in vivo produced CAR-T cells that target B cell follicles as a treatment for HIV

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 DCAI-D (10)]


NIH_SPENDING_CATS: Acquired Cognitive Impairment;Aging;Alzheimer's Disease;Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD);Brain Disorders;Dementia;Neurodegenerative;Neurosciences

ORG_CITY: TORRANCE

ORG_NAME: NEUROINDX INC.

PHR: NARRATIVE It has been widely demonstrated that microtubule (MT) dysfunction can be the cause of neurodegenerative processes. Therefore, MT-targeting approaches represent one of the most promising strategies to treat ADRDs. Here, we propose to develop an on-chip drug discovery assay for rapid functional evaluation of candidate MT binding molecules for their effect on MT stability and transport. The development of an MT microfluidic chip for cell-free drug screening will enable the identification of new therapeutics in a more efficient and effective manner ultimately accelerating the development of new therapeutics for these diseases.

PI_NAMEs: KARSTEN, STANISLAV  (contact)

PROGRAM_OFFICER_NAME: MARTIN, ZANE

PROJECT_TERMS: Acceleration;Affect;Alzheimer's disease related dementia;Animal Model;Binding;Biological Assay;Biological Models;candidate identification;Cell Culture Techniques;Cell division;Cell Physiology;Cells;Cessation of life;Chemicals;chromatin immunoprecipitation;Clinical Trials;Complex;Consumption;cost;cost effectiveness;Cytoskeleton;Data;Defect;density;design;Detection;detection limit;Development;discodermolide;Disease;drug candidate;drug development;drug discovery;drug efficacy;Drug Modulation;Drug Screening;drug testing;Ensure;epothilone D;Epothilones;Evaluation;Functional disorder;Funding;Geometry;Goals;high-throughput drug screening;hyperphosphorylated tau;Image;improved;In Vitro;in vitro Model;Intracellular Transport;Kinesin;Label;Life;Link;lithography;MAPT gene;Measures;meetings;Methods;Microfabrication;Microfluidic Microchips;Microtubule Stabilization;Microtubule-Associated Proteins;Microtubules;migration;milliliter;Modeling;Modification;Molecular;nano;nanomolar;Nerve Degeneration;Neurodegenerative Disorders;Neurofibrillary Tangles;neuron component;Neuronal Dysfunction;Neurons;novel;novel therapeutics;Outcome Measure;Paclitaxel;Pathologic;Pathology;Patients;Pharmaceutical Preparations;Phase;Play;Predisposition;prevent;Process;prototype;Public Health;rapid test;Reliability of Results;Reproducibility;Role;screening;Sensitivity and Specificity;Specificity;Speed;Structure;System;targeted agent;tau Proteins;Techniques;Testing;Therapeutic;therapeutic target;Time;tool;trafficking;Translating;Translation Process;treatment strategy;Validation

PROJECT_TITLE: On-Chip Assay for Identifying Candidate Microtubule Binding Drugs to Treat ADRDs


NIH_SPENDING_CATS: Biotechnology;Cancer;Digestive Diseases;Immunotherapy;Pancreatic Cancer;Rare Diseases

ORG_CITY: HOUSTON

ORG_NAME: MARKER THERAPEUTICS, INC.

ORG_STATE: TX

PHR: NARRATIVE Pancreatic cancer is the 3rd most deadly cancer in the US, with only ~11% of patients surviving more than 5 years. Cell therapies have shown great promise in blood cancers by targeted killing of cancer cells, however this has been less successful in pancreatic cancer due to the hostile environment surrounding the tumor. We propose a binary cell therapy for pancreatic cancer, consisting of one product which transforms the hostile tumor microenvironment enabling a second product to target and kill pancreatic cancer cells.

PI_NAMEs: VERA, JUAN FERNANDO (contact)

PROJECT_TERMS: Address;Amendment;Antigen Presentation;antigen-specific T cells;Antigens;Autologous;Automobile Driving;cancer cell;cancer diagnosis;Cancer Etiology;cancer type;Cell Death Induction;cell growth;cell killing;Cell Physiology;Cell Therapy;Cells;Cellular immunotherapy;Cessation of life;Circulation;Clinic;Clinical;clinical application;clinical efficacy;clinical implementation;Clinical Trials;Cryopreservation;CTAG1 gene;cytokine;Data;Diagnosis;Disseminated Malignant Neoplasm;Dose;Electroporation;Engineering;Environment;experience;FDA approved;Future;Gene Proteins;Generations;Half-Life;Hematologic Neoplasms;Hematopoietic Neoplasms;Immune Evasion;Immunologic Surveillance;improved;In Vitro;in vivo;Kinetics;Libraries;Malignant neoplasm of pancreas;Malignant Neoplasms;manufacture;manufacturing process;mRNA Expression;Mus;novel;pancreatic cancer cells;pancreatic cancer patients;partial response;Patients;phase 1 study;pre-clinical;preferentially expressed antigen in melanoma;prevent;Process;Production;Property;protein expression;Proteins;Protocols documentation;radiological imaging;Recombinant Fusion Proteins;Recombinants;response;Running;Safety;safety assessment;scale up;Schedule;Signal Transduction;Site;Small Business Innovation Research Grant;Solid Neoplasm;Specificity;success;Survival Rate;survivin;synergism;System;T cell therapy;T-Lymphocyte;Toxic effect;trafficking;Transgenic Organisms;Treatment Efficacy;tumor;Tumor Antigens;Tumor Escape;tumor microenvironment;tumor-immune system interactions;Validation

PROJECT_TITLE: Controlling Tumor Immune Escape in Pancreatic Cancer using a Dual T Cell Product Strategy

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 CDPT-V (13)]


NIH_SPENDING_CATS: Aging;Assistive Technology;Behavioral and Social Science;Bioengineering;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Hearing Loss;Machine Learning and Artificial Intelligence;Networking and Information Technology R&D (NITRD);Neurosciences;Prevention;Racial and Ethnic Minority Health Research;Rehabilitation;Rural Health;Social Determinants of Health

ORG_CITY: LORETTO

ORG_NAME: APPLIED UNIVERSAL DYNAMICS CORPORATION

PHR: Project Narrative Nearly 44 million Americans experience some hearing loss, but as much as 86% of adults who could benefit from hearing aid devices (HAD) choose not to use them. HAD usage is disproportionately lower among rural and minority populations. Concerns about access, cost, comfort, effectiveness, and satisfaction are key barriers to HAD usage.

PI_NAMEs: GIBSON, PAUL  (contact)

PROGRAM_OFFICER_NAME: HARRELL, ERIN

PROJECT_TERMS: Adult;Algorithms;American;Audiology;Auditory;care delivery;Caring;Cellular Phone;Clinic;Communities;Computer software;Consumption;cost;Development;Devices;Effectiveness;Engineering;experience;Face;feasibility testing;Funding Opportunities;Goals;graphical user interface;Health Professional;Health Services Accessibility;Hearing;Hearing Aids;hearing impairment;hispanic community;Human;improved;Insurance Coverage;interest;Intuition;Latino;Lead;Leadership;Low income;Machine Learning;machine learning algorithm;Masks;medical specialties;Mexican Americans;microphone;Minority Groups;mobile computing;Modeling;Neural Network Simulation;Noise;older adult;Performance;Persons;Phase;Population;Price;Principal Investigator;prototype;Provider;recurrent neural network;Research;research and development;Research Personnel;rural America;rural area;Rural Population;satisfaction;Services;Small Business Innovation Research Grant;smartphone application;Speech;Speech Intelligibility;Stream;System;Systems Integration;Technology;Testing;Time;training data;Underserved Population;Validation;Voice;wireless

PROJECT_TITLE: Smartphone Machine Learning Speech Enhancement System for Hearing Aid Devices for the Underserved and Rural Populations


NIH_SPENDING_CATS: Biotechnology;Genetics;Human Genome

ORG_CITY: BRANFORD

ORG_NAME: RNACONNECT INC

PHR: Project Narrative This project will develop, optimize and produce a family of easy-to-use RT-PCR and RNA sequencing kits based on the exceptionally processive reverse transcriptase ultraMarathonRT (uMRT). uMRT represents the commercial entry of a powerful new generation of ‘enzymatic hardware’ that will enable the scientific community, for the first time, to read and detect variation within whole transcriptomes. This means previously invisible information within RNAs that is critical for understanding all layers of biological function can now be revealed and measured. With these new, easy-to-use uMRT kits, RNA innovation and discovery will now be accessible to the broader biomedical and biotechnology community. History has shown that innovation typically follows the creation of more powerful scientific tools, such as the creation of the commercial biotechnology industry that followed the development of recombinant DNA technology in the 1970s, or the emerging field of gene editing therapeutics following the discovery of CRISPR enzymes. The introduction of uMRT products is a similar watershed moment.

PI_NAMEs: GUO, LI-TAO  (contact)

PROGRAM_OFFICER_NAME: SAKALIAN, MICHAEL

PROJECT_TERMS: 2019-nCoV;agricultural community;Biological Assay;Biological Markers;Biological Process;Biological Sciences;Biology;Biotechnology;Buffers;cDNA Library;Cells;Clinical;clinical practice;Clustered Regularly Interspaced Short Palindromic Repeats;Cold Chains;commercialization;Communities;Complementary DNA;Coronavirus;Dangerousness;Data;Detection;Development;Devices;Disease;DNA Sequence;drug market;Ebola;Economics;Engineering;Enzymes;epitranscriptomics;Family;frontier;Funding;Gene Expression;Generations;Genes;Genetic Engineering;Genetic Materials;Genome;Goals;Grant;Human;improved;Industry;Influenza;Infrastructure;innovation;Laboratories;Length;Life;manufacture;Market Research;Marketing;Measures;Medical;Medicine;Messenger RNA;Methods;Molecular;Monitor;mutant;pathogen;Patients;Performance;Plants;Population;Production;professor;Protein Isoforms;Proteins;Quantitative Reverse Transcriptase PCR;Reaction;Reagent;Recording of previous events;Refrigeration;Research;Research Personnel;Reverse Transcriptase Polymerase Chain Reaction;RNA;RNA Degradation;RNA Sequences;RNA Splicing;RNA vaccine;RNA-Directed DNA Polymerase;Role;Sales;Shipping;single cell sequencing;Site;Small Business Innovation Research Grant;Specific qualifier value;Standardization;Structure;Technology;Temperature;Testing;therapeutic genome editing;thermostability;Time;tool;transcriptome;transcriptome sequencing;transcriptomics;Translating;Universities;Untranslated RNA;Variant;Virus;Work

PROJECT_TITLE: Develop, Optimize and Commercialize UltraMarathonRT: A new enzyme for unbiased transcriptomic and epitranscriptomic characterization of RNAs regardless of length or composition.

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 MCST-G (15)]


NIH_SPENDING_CATS: Assistive Technology;Bioengineering;Cardiovascular;Clinical Research;Health Services;Heart Disease

ORG_CITY: Austin

ORG_NAME: ALLEVIANT MEDICAL, INC.

PHR: NARRATIVE Congestive heart failure is a chronic and progressive condition that currently affects over 6 million patients in the US and poses a major public health burden. Symptoms of the disease are due, in large part, to elevated left atrial pressure, which results from failure of the heart to adequately eject blood from its main pumping chamber (left ventricle). This proposal seeks to advance a novel, no-implant interatrial shunt towards commercialization which relieves left atrial pressure to reduce the symptoms and morbidity associated with heart failure.

PI_NAMEs: PATE, THOMAS DIFFLEY (contact)

PROGRAM_OFFICER_NAME: LIU, SONGTAO

PROJECT_TERMS: acute care;Adoption;Adverse event;Affect;Age;Ambulatory Care;American;Angiography;arm;Attention;Awareness;Blood;Blood Vessels;Cardiac;cardiac implant;Cardiology;Cardiovascular system;Categories;Catheters;Chronic;Classification;Clinical;Clinical Data;Clinical Research;clinical risk;Clinical Trials;Coagulation Process;Code;college;commercial launch;commercialization;Congestive Heart Failure;Contracts;Controlled Clinical Trials;Data Set;Death Rate;design;design verification;Development;Devices;Disadvantaged;Disease;EFRAC;Elements;Equipment;Equipment Malfunction;Event;Excision;failure Implantation;FDA approved;first-in-human;Foreign Bodies;Fracture;Funding;Future;Goals;health care disparity;Health Expenditures;Health Policy;Heart;Heart Atrium;Heart failure;heart failure with reduced ejection fraction;high risk;high volume manufacturing;Hospitalization;Human;Implant;improved;Incidence;Injections;Intervention;Leadership;Left;Left atrial structure;Left Ventricular Ejection Fraction;Left ventricular structure;Lung;manufacture;manufacturing capabilities;manufacturing process;manufacturing scale-up;Marketing;Medical;Medical Societies;Medicare/Medicaid;meetings;Metals;migration;Modification;Molds;Morbidity - disease rate;mortality;new technology;New York;novel;Outcome;Pathway interactions;patient advocacy group;patient population;patient prognosis;Patients;payment;pharmacologic;Phase;Population;pre-clinical;preservation;pressure;Procedures;Process;Production;programs;Public Health;Pump;Qualifying;Quality of life;Randomized;Randomized, Controlled Trials;Readiness;reduce symptoms;Reporting;Right atrial structure;Risk;Safety;Shunt Device;Signal Transduction;Small Business Innovation Research Grant;Societies;Source;Stents;Sterilization;success;supply chain;symposium;symptomatic improvement;Symptoms;System;Technology;Testing;Therapeutic;Therapeutic Embolization;Therapeutic Intervention;Thrombus;Training and Education;United States Centers for Medicare and Medicaid Services;United States National Institutes of Health;Validation;Walking;Woman;Work

PROJECT_TITLE: Advancing Commercial Readiness of a No-implant Interatrial Shunt Therapy to Treat Heart Failure

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 MCST-B (19)]


ADMINISTERING_IC: HG

IC_NAME: NATIONAL HUMAN GENOME RESEARCH INSTITUTE

NIH_SPENDING_CATS: Genetics;Human Genome

ORG_CITY: WOODCLIFF LAKE

ORG_NAME: DIRECTSEQ BIOSCIENCES, INC.

PHR: Though more than 170 RNA modifications are identified, their functions largely remain elusive due to current technological limits. The proposed research seeks to evaluate the potential of mass spectrometry-based sequencing for unbiased, single-base resolution sequencing of RNA modifications, a crucial step in unraveling their impact on human health.

PI_NAMEs: ZHANG, SHENGLONG  (contact)

PROGRAM_OFFICER_NAME: NOVA, IAN CURTIS

PROJECT_TERMS: Accounting;Acids;base;cell growth regulation;Chemicals;Codon Nucleotides;commercialization;Communities;Complementary DNA;Complex;Data;Data Analyses;Databases;Dependence;design;Digestion;Disease;disease model;DNA biosynthesis;Electronics;Enhancement Technology;epitranscriptome;Face;Health;Heterogeneity;High-Throughput Nucleotide Sequencing;Human;Hydrolysis;improved;insight;Length;Link;Location;Malignant Neoplasms;Maps;Mass Spectrum Analysis;Measurable;Melanoma;Messenger RNA;Methods;Mitochondria;model organism;Modeling;Modification;nanopore;neglect;Nervous System Disorder;Neurologic;next generation;next generation sequencing;Non-Insulin-Dependent Diabetes Mellitus;Nucleosides;Nucleotides;Oligonucleotides;Organism;Physiological;Preparation;preservation;Process;Protocols documentation;Research;Resolution;response;Ribonucleases;RNA;RNA Degradation;RNA Sequences;RNA-Directed DNA Polymerase;Sampling;Series;Signal Transduction;Site;stoichiometry;tandem mass spectrometry;Techniques;Technology;Testing;Time;Training;transcriptome sequencing;transcriptomics;Transfer RNA;two-dimensional;Untranslated RNA

PROJECT_TITLE: High-throughput Direct Sequencing and Quantitative Mapping of RNA Modifications using Mass Spectrometry.

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 MCST-J (10)]


NIH_SPENDING_CATS: Breastfeeding, Lactation and Breast Milk;Nutrition;Pediatric;Prevention

ORG_CITY: LAWRENCEVILLE

ORG_NAME: PUMPKIN BABY INC.

PHR: Narrative Breastmilk is often stored frozen to facilitate continued breastfeeding of infants, especially as nursing mothers return to work, however, the freeze-thaw process disrupts the structural integrity of breastmilk, lowers its nutritive value, and renders it susceptible to rancidity, leading to infant undernutrition and/or rejection of breastmilk. To address this issue, PumpKin Baby is developing a method to retain the structural integrity and nutritional value of freeze-thawed breastmilk using a food-derived, GRAS-based formulation that can simply be added to breastmilk prior to freezing. By combining compounds that operate using different biological, physical, and chemical mechanisms (e.g., lipolysis-targeting compounds, stabilizing agents, and antioxidants), this technology can be used to maintain the structural integrity, nutritional value, and fresh taste of frozen breastmilk.

PI_NAMEs: SILPE, JUSTIN E (contact)

PROGRAM_OFFICER_NAME: ROSS, SHARON A

PROJECT_TITLE: Extending shelf life and preserving the nutritional value of freezer-stored breastmilk


ORG_CITY: Irvine

ORG_NAME: RESHAPE LIFESCIENCES, INC.

PHR: Project Narrative Current Type 2 Diabetes Mellitus treatments include life-style management, pharmaceuticals and may include bariatric surgery for the morbidly obese. ReShape Lifescience’s Targeted Dual Neuromodulation Therapy (TDN Therapy) provides a disruptive therapy in which an implantable neuromodulation device detects high blood glucose levels and then blocks nerve impulse along the hepatic branch of the vagus nerve while concurrently stimulating the celiac branch of the vagus nerve to reduce blood glucose levels. The proposed grant intends to determine if lower HFAC amplitudes of the TDN signal will maintain glycemic control, assess autonomic function and evaluate off-target effects.

PI_NAMEs: WAATAJA, JON JAMES (contact)

PROGRAM_OFFICER_NAME: COOKE, BRAD

PROJECT_TERMS: Abdomen;Acute;Alloxan;American;Animal Model;bariatric surgery;battery size;Biological Sciences;Blood Glucose;blood glucose regulation;Bluetooth;Capital;cardiovascular effects;Cardiovascular system;Cervical;Child;Clinic;Clinical Treatment;Clinical Trials;commercialization;comorbidity;Complex;Continuous Glucose Monitor;design;Development;Devices;Diabetes Mellitus;diabetic;Disease remission;Doctor of Philosophy;effective therapy;Effectiveness;Elderly;Endocrinologist;Engineering;Epilepsy;Esophagus;Esthesia;euglycemia;experience;experimental study;Family suidae;Frequencies;Functional disorder;Funding;Future;glycemic control;Goals;Grant;Heart;Heart Rate;heart rate variability;Hepatic;Implant;improved;in vivo;innovation;Knowledge;Life Style;Machine Learning;Measurement;Measures;Medicine;Minnesota;Morbid Obesity;Nerve Block;neuroregulation;next generation;non-compliance;Non-Insulin-Dependent Diabetes Mellitus;obese patients;obese person;OGTT;Organ;Outcome;Pancreas;Patient Compliance;Patients;Pharmacologic Substance;Phase;phase 1 study;Physiologic pulse;porcine model;Prediabetes syndrome;preservation;Privatization;Procedures;professor;Protocols documentation;rate of change;Reporting;Research;Risk;Safety;Shapes;side effect;Signal Transduction;Small Business Innovation Research Grant;smart device;Smooth Muscle;System;targeted delivery;Technology;Testing;Therapeutic;Titrations;Treatment Cost;Type 2 diabetic;Universities;vagus nerve stimulation;Vagus nerve structure;Validation;Work

PROJECT_TITLE: Diabetic Targeted Dual Neuromodulation Parametric Optimization


NIH_SPENDING_CATS: Bioengineering;Clinical Research;Conditions Affecting the Embryonic and Fetal Periods;Contraception/Reproduction;Infertility;Maternal Health;Maternal Morbidity and Mortality;Pediatric;Perinatal Period - Conditions Originating in Perinatal Period;Pregnancy;Preterm, Low Birth Weight and Health of the Newborn;Prevention;Women's Health Research

ORG_CITY: GRAND RAPIDS

ORG_NAME: AKNA HEALTH LLC

ORG_STATE: MI

PHR: Narrative version We aim to introduce a first-trimester testing platform to detect early pregnancy complications, allowing timely interventions for high-risk pregnancies. Using a non-intrusive method akin to a pap test, we will quantify protein biomarkers indicative of the risk level for pregnancy disorders. This approach will offer insights comparable to ultrasound but much earlier in the pregnancy, facilitating personalized care plans. Our goal is to launch a point- of-care perinatal test, revolutionizing care for mothers and their babies.

PI_NAMEs: DREWLO, SASCHA  (contact)

PROJECT_TERMS: 2 year old;Abnormal placentation;Address;adverse outcome;Archives;at-risk pregnancies;Biological Markers;biomarker panel;Birth Weight;Blood;Blood flow;Blood specimen;Caring;Cell Lineage;Cells;Cervical;Classification;Clinic;Clinical;Clinical Research;clinically relevant;cohort;Collaborations;Collection;commercialization;Companions;Complement;cost;cost effective;Data;Data Analyses;Detection;Development;Devices;Diagnostic;diagnostic platform;Diagnostic Reagent Kits;diagnostic strategy;diagnostic tool;digital;disability;Disease;disorder risk;Early Diagnosis;Early identification;Early Intervention;early pregnancy;early pregnancy loss;Ensure;Enzyme-Linked Immunosorbent Assay;Evaluation;Exclusion;experience;Face;Fetal Growth Retardation;Fetus;First Pregnancy Trimester;FLT1 gene;Future;Gases;Goals;Growth;Health;Health Insurance Portability and Accountability Act;Healthcare;healthy pregnancy;high risk;High-Risk Pregnancy;Home;Hospitals;indexing;Infant;Informed Consent;innovation;insight;Intervention;Laboratories;Lateral;Legal patent;Link;Liquid substance;Measures;Methodology;Methods;Modeling;Mothers;Newborn Infant;North America;Nutrient;Outcome;Pap smear;Pathology;Patient Recruitments;Patients;Perinatal;Perinatal Care;perinatal complications;Perinatal Disorder;perinatal intervention;perinatal medicine;Perinatology;personalized care;Phase;Placenta;Placental Insufficiency;placental trophoblasts;Placentation;Plasma;point of care;point of care testing;Positioning Attribute;Pre-Eclampsia;Predictive Value;Pregnancy;Pregnancy Complications;pregnancy disorder;Pregnancy Outcome;Pregnancy Proteins;pregnant;Pregnant Women;protein biomarkers;protein expression;Proteins;Records;recruit;Regression Analysis;Regulation;Reporting;Reproductive Health;Research;Research Personnel;Risk;sample archive;Sampling;Savings;screening;Secure;Severities;Signal Transduction;Small Business Innovation Research Grant;Specimen;Spontaneous abortion;Structure;Techniques;Technology;Testing;ultrasound;validation studies;Vision;Woman

PROJECT_TITLE: Point-of-care testing for perinatal risks in early pregnancy


NIH_SPENDING_CATS: Behavioral and Social Science;Bioengineering;Clinical Research;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Health Services;Machine Learning and Artificial Intelligence;Networking and Information Technology R&D (NITRD);Pediatric;Prevention;Primary Health Care;Racial and Ethnic Minority Health Research;Social Determinants of Health;Telehealth

ORG_CITY: SEATTLE

ORG_NAME: BSOLUTIONS, INC.

ORG_STATE: WA

PHR: This Phase I application introduces Cribsy, an innovative smartphone-based telehealth screener for neuromotor risks in infants. Cribsy leverages the versatility of smartphones and AI to fill the gap between the prevalence of at-risk infants and the scarcity of resources for developmental screening and aims to reduce health inequities in underserved communities. The ultimate goal of Cribsy is to ensure that no child, regardless of circumstances, is denied the opportunity for early risk screenings.

PI_NAMEs: MODAYUR, BHARATH  (contact)

PROGRAM_OFFICER_NAME: OREILLY, JULIA JIAQI

PROJECT_TERMS: Academy;Address;Adoption;Age;American;Artificial Intelligence;artificial intelligence method;artificial intelligence model;Automation;Black race;Brain;Caring;Cellular Phone;Child;Child health care;Childhood;Classification;Clinic;Clinical;Collaborations;commercialization;Continuity of Patient Care;cost;Creativeness;Data;data modeling;Decision Making;Development;Developmental Disabilities;developmental disease;Devices;Diagnosis;Early Intervention;early screening;Environmental Risk Factor;Evaluation;experience;Family;feasibility testing;Feedback;Funding;Goals;Health;health inequalities;high risk;high risk infant;Hispanic;Home;Human Resources;Immunization;Impairment;Infant;innovation;insight;Intervention;Machine Learning;Marketing;Measures;Methodology;Methods;Minority;Minority Groups;Modeling;Motor;Movement;Occupational Therapist;outreach;Parents;Pathway interactions;Pediatrics;Phase;Pilot Projects;Positioning Attribute;post-pandemic;preterm newborn;Prevalence;prevent;Probability;Process;programs;Property;prototype;Public Health;Race;Recommendation;recruit;repository;Research;Research Design;Resource-limited setting;Resources;Risk;Running;rural area;Schools;screening;Screening procedure;Sensitivity and Specificity;service intervention;Social Work;Standardization;telehealth;Time;tool;Training;underserved area;underserved community;Update;user-friendly;Validation;validation studies;Videoconferencing;Visit;Washington;Well Child Visits

PROJECT_TITLE: Cribsy: A platform for home-based automated developmental risk screening

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 BP-C (10)]


ADMINISTERING_IC: VA

FUNDING_MECHANISM: OTHERS

IC_NAME: Veterans Affairs

ORG_CITY: SAN FRANCISCO

ORG_NAME: VETERANS AFFAIRS MED CTR SAN FRANCISCO

PHR: The main goal of my research is to support the mission of VA Healthcare through studies that will facilitate better treatment of service personnel and veterans with stroke and diabetes. My research program will improve our understanding why diabetes worsens the brain inflammation in the event of ischemic stroke by looking into the molecular mechanisms involved in the process. It will also provide clues in how diabetes increases clotting after stroke, because inflammation can worsen clotting. As such, targeting these crucial mechanisms can alleviate harmful effects caused by diabetes and lessen stroke brain injury.

PI_NAMEs: LIU, JIALING  (contact)

PROJECT_TERMS: Affect;Age;Anaphylatoxins;Angiography;arteriole;Attenuated;Award;Behavioral;Biological;blood perfusion;Brain;brain cell;Brain hemorrhage;Brain Injuries;C3AR1 gene;career;Cells;cerebral vein;Cerebrum;Chronic;Clinical;Coagulation Process;cognitive function;cognitive recovery;Collaborations;Communities;Community Participation;Complement;complement system;conditioning;Defect;Development;Diabetes Mellitus;efficacy evaluation;Electric Stimulation;Electrical Stimulation of the Brain;Encephalitis;Event;Exhibits;Failure;functional outcomes;Funding;Funding Agency;General Population;Goals;Grant Review;Health;Healthcare;Hippocampus;Human Resources;Immune;Immune system;Impairment;improved;Incidence;Individual;Inflammation;Injury;Interferon Type II;Interferons;International;Intervention;Ischemia;ischemic conditioning;Ischemic Preconditioning;Ischemic Stroke;Journals;Leptomeninges;Leukocyte Rolling;Leukocytes;Mediating;member;Memory;Mentors;Metabolic;Metabolic Diseases;Metabolic syndrome;migration;Mission;Molecular;multiphoton imaging;Mus;Myeloid Cells;Natural regeneration;Nerve Regeneration;neural;neurogenesis;neuroinflammation;Neurons;neuroprotection;Non-Insulin-Dependent Diabetes Mellitus;novel;Obesity;optical imaging;Outcome;Pathologic;Pathway interactions;Patients;Pattern;Peer Review;Perfusion;Peripheral;pharmacologic;Platelet Activation;Platelet aggregation;post stroke;Prevalence;Process;programs;Progress Reports;receptor;Recovery;Recovery of Function;Research;Research Personnel;response;Risk;Risk Factors;Role;Scientist;Services;Severities;Signal Transduction;Societies;Stroke;stroke outcome;stroke patient;stroke risk;Synapses;Technology;Therapeutic;Therapeutic Effect;Therapeutic Intervention;Thrombus;Time;Toll-like receptors;Traumatic Brain Injury;Treatment Efficacy;treatment services;vascular risk factor;Veterans;Work

PROJECT_TITLE: BLRD Research Career Scientist Award Application

STUDY_SECTION_NAME: Special Emphasis Panel[ZRD1 RCSR-N (01)]


NIH_SPENDING_CATS: Assistive Technology;Behavioral and Social Science;Bioengineering;Clinical Research;Clinical Trials and Supportive Activities;Disability Research;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Nutrition;Obesity;Prevention;Rehabilitation

ORG_CITY: PITTSBURGH

ORG_NAME: NURELM E-BUSINESS SOFTWARE

PHR: Project Narrative Wheelchair users are twice as likely as the general population to be overweight or obese, which leads to secondary health consequences and exacerbates mobility and participation limitations. It is well known that frequent weight monitoring facilitates weight management, which is impossible for most wheelchair users who do not have access to a bodyweight scale. The Fast In-Bed (FIT) Platform we will develop in this project will provide passive and daily weight monitoring for wheelchair users to better manage their weight, and subsequently improve their overall health.

PI_NAMEs: PEARLMAN, JONATHAN L;SHAABAN, SAMI  (contact)

PROGRAM_OFFICER_NAME: AJISAFE, TOYIN DELE

PROJECT_TERMS: Address;Adult;Apple;Beds;Body Weight;Body Weight decreased;Chronic;commercialization;Communities;Complex;Computer software;Congestive Heart Failure;Control Groups;cost effective;Couples;decubitus ulcer;design;Development;disability;Disadvantaged;efficacy evaluation;eHealth;Equilibrium;feasibility trial;Feedback;fitness;General Population;Goals;Health;Health Care Costs;health disparity;heuristics;Home;improved;Individual;Internet of Things;Intervention;Interview;Life Style;manufacturing scale-up;Measures;meetings;Mobility decline;Monitor;Obesity;obesity risk;Outcome;Overweight;Participant;Perception;person centered;Persons;Physical activity;Population;Randomized;Randomized, Controlled Trials;Recommendation;Risk;Secondary to;Self Efficacy;Sleep;sleep quality;System;Testing;Time;tool;Underserved Population;United States;usability;Walking;Weight;weight loss intervention;weight loss program;weight maintenance;Weight maintenance regimen;Wheelchair user;Work

PROJECT_TITLE: Development and Commercialization of a weight monitoring platform for wheelchair users

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 CCHI-J (10)]


NIH_SPENDING_CATS: Acquired Cognitive Impairment;Aging;Alzheimer's Disease;Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD);Basic Behavioral and Social Science;Behavioral and Social Science;Brain Disorders;Dementia;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Neurodegenerative;Neurosciences;Social Determinants of Health

ORG_CITY: BETHLEHEM

ORG_NAME: HAGER BIOSCIENCES, LLC

PHR: Optimization of Novel Potassium Channel Kv1.3 Blockers as Potential Alzheimer's Disease Therapeutics Project Narrative PUBLIC HEALTH RELEVANCE: Age-associated impairments, dementias, and cognitive decline due to Alzheimer's Disease (AD) and other neurodegenerative disorders such as PD and HD exact an almost incalculable socio- economic burden on humankind. Neuroinflammation (NI) is a key contributing factor to the underlying etiology leading to these debilitating neurodegenerative disorders; and unfortunately, current treatments for AD and other neurodegenerative diseases are mainly palliative and become less effective as disease progresses. This body of work should provide highly impactful and innovative disease-modifying treatment modalities for AD and other neurodegenerative disorders via the modulation of ion channels implicated in NI and subsequent neurodegeneration.

PI_NAMEs: BUTERA, JOHN A (contact)

PROJECT_TERMS: ABCB1 gene;abeta accumulation;Affect;age-related disease;aging population;aging related;Alzheimer's Disease;Alzheimer's disease brain;Alzheimer's disease model;Alzheimer's disease therapeutic;Amyloid beta-Protein;analog;Animal Disease Models;Animal Model;APP-PS1;Attenuated;Autoimmune Diseases;Autopsy;Binding Proteins;Biological Assay;Biological Sciences;Brain;brain tissue;Calcium;Cardiovascular Diseases;Cells;Central Nervous System;cerebral atrophy;channel blockers;chemokine;Chinese Hamster Ovary Cell;Chronic;clinical development;Cognition;cytokine;Defense Mechanisms;Dementia;design;Development;Disease;Economic Burden;economic cost;efficacy study;Elderly;Electrophysiology (science);Equilibrium;Etiology;Extracellular Matrix;Family;follow-up;Frontotemporal Lobar Degenerations;Funding;Funding Mechanisms;glial activation;Goals;Health;Human;human disease;Immunohistochemistry;Immunosuppression;Impaired cognition;Impairment;improved;In Vitro;in vivo;Inflammatory;Inflammatory Response;inhibitor;innovation;Investigation;Investments;Ion Channel;Ion Channel Gating;Kv1.3 potassium channel;Lead;lead optimization;lead series;Libraries;Malignant Neoplasms;Measures;Mediating;Medical;member;Mental disorders;Microglia;Microsomes;misfolded protein;Modality;Molecular Target;molecular targeted therapies;Mononuclear;mouse model;Mus;Natural regeneration;Nerve Degeneration;Neurodegenerative Disorders;Neurofibrillary Tangles;Neuroglia;neuroinflammation;neuron loss;Neuronal Plasticity;Neurons;Nitrogen;novel;Oxygen;palliative;Pathology;Peptides;Permeability;Phagocytes;Pharmaceutical Chemistry;Pharmaceutical Preparations;Pharmacologic Substance;pharmacophore;Phase;Phenotype;physical property;Plasma;Positioning Attribute;Potassium;Process;Production;Property;Protocols documentation;public health relevance;Quality of life;Research;response;risk mitigation;Rodent Model;Role;scaffold;screening;Senile Plaques;Series;Signal Transduction;Small Business Innovation Research Grant;small molecule;small molecule inhibitor;socioeconomics;Solubility;Spinal Cord;stable cell line;synaptic function;systemic inflammatory response;T-Lymphocyte;tau Proteins;therapeutic target;tissue injury;Tissues;Transfection;voltage;voltage clamp;Voltage-Gated Potassium Channel

PROJECT_TITLE: Optimization of Novel Potassium Channel Kv1.3 Blockers with Potential as Alzheimer's Disease Therapeutics